NCT06433661View on ClinicalTrials.gov

A Research Study of the Effect of Food on Etavopivat in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

July 6, 2024

Study Completion Date

July 8, 2024

Conditions

Healthy Volunteers Sickle Cell Disease, Thalassemia

Interventions

DRUG

Etavopivat

Participants will receive single dose of oral Etavopivat in each treatment period.

Trial Locations (1)

84124

ICON-Salt Lake City, Salt Lake City

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY